Beam Therapeutics Inc. (BEAM) is listed on NasdaqGS in the Healthcare sector Β· Biotechnology industry. The current price is 29.05, down -0.84% from the previous close. Market cap is approximately $3B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
BEAM's ROE at -8.18% lags the market. ROE stuck below 5% for 1-2 years can be a value trap signal β verify the fundamental story before assuming recovery.
Beam Therapeutics Inc.'s elevated D/E of 23.17 either reflects an aggressive growth-via-debt strategy or balance sheet stress. Operating cash flow trend is the cleanest tell.
Revenue is shrinking -94.20%. Even with cost discipline holding up earnings, multiple compression typically follows when top-line visibility is missing.
Demographic-driven structural demand growth is a long-running tailwind for healthcare.
Beam Therapeutics Inc. trades near the midpoint (45%) of its 52-week range (17.74β38.26). With the price anchored to neither extreme, valuation and earnings tend to be more informative than price direction here.
The day's high-to-low spread reached 5.82%, with a -0.84% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
Beam Therapeutics Inc. (BEAM) is listed on NasdaqGS, with recent volume of 537,356 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.